March 10, 2015

ANI Pharmaceuticals acquired the approved abbreviated new drug application for flecainide acetate tablets USP in 50-mg, 100-mg and 150-mg dosage strengths.

March 10, 2015

Teva Pharmaceuticals will sell its Sellersville, Penn., facility to G&W Labs. According to Teva, the move supports its mission of streamlining operations by reducing excess manufacturing capacity.

February 17, 2015

Teva Pharmaceuticals on Tuesday announced the launch of generic versions of Lovenox (enoxaparin sodium injection) as well as generic Zyvox (linezolid) injection. 

 

February 3, 2015

Teva Pharmaceuticals on Tuesday announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in 10-mg dosage strength.

January 20, 2015

Teva Pharmaceutical on Tuesday announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA vs. Sandoz et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for Copaxone (glatiramer acetate injection) 20 mg/mL.

January 9, 2015

Teva Pharmaceuticals on Friday announced the launch of linezolid injection, the generic equvialent to Zyvox injection from C.P. Pharmaceuticals.

January 7, 2015

Teva Pharmaceutical on Tuesday announced the Food and Drug Administration approved the launch of the company's valsartan tablets, the generic version of Diovan tablets from Novartis. 

 

December 23, 2014

Teva Pharmaceutical today announced that the Food and Drug Administration has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe Granix for either in-office or at home use.

December 19, 2014

Teva Pharmaceutical announced that the Food and Drug Administration approved QNasl (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis in children ages 4 years to 11 years.

December 11, 2014

Teva Pharmaceuticals on Thursday announced the availability of levalbuterol inhalation solution, USP (concentrate), a generic equivalent to Xopenex inhalation solution concentrate. 

December 2, 2014

Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII.

December 1, 2014

Teva Pharmaceutical on Monday announced the launch of a generic version of Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the United States. 

November 11, 2014

Teva Pharmaceuticals announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in a 5-mg strength.

November 7, 2014

Teva Pharmaceutical on Friday announced positive findings from a Phase III clinical study that examined the safety and efficacy of Qnasl.

September 4, 2014

Teva Pharmaceutical on Thursday announced the launch of generic Baraclude (entecavir) tablets in 0.5-mg and 1-mg dosage strengths. The company was the first to file, giving it 180 days of marketing exclusivity for the drug. 

September 3, 2014

Teva Pharmaceutical on Wednesday announced the launch of SYNCareTM, a program designed to support patients taking Synribo (omacetaxine mepesuccinate) for at-home injection.

September 3, 2014

Teva Pharmaceutical on Wednesday announced that a positive judgment has been given by the U.K. High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort.

July 31, 2014

Teva Pharmaceuticals on Thursday announced results for second-quarter 2014, which included revenues of $5 billion, an increase of 2% compared with the same period last year.

July 22, 2014

The Food and Drug Administration has granted tentative approval to Teva Pharmaceutical for abacavir sulfate and lamivudine tablets, according to agency records.

July 14, 2014

Teva Pharmaceuticals on Monday announced that the Food and Drug Administration has accepted the company's new drug application for albuterol multi-dose dry-powder inhaler, a breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.

June 6, 2014

Teva Pharmaceuticals announced the launch of Mimvey Lo (estradiol and norethindrone acetate tablets, USP), the generic equivalent to Activella tablets.

June 3, 2014

Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, on Tuesday announced that Teva has entered into a definitive agreement to acquire Labrys in a deal for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones.

May 29, 2014

Teva Pharmaceuticals announced the introduction and availability of dexmethylphenidate hydrochloride extended-release capsules, CII, in 15 mg and 30 mg strengths.

May 23, 2014

Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of asthma in patients 5 years of age and older.